Skip to content

CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Contribution in Pathology Diagnosis and Molecular Biology

CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Pathology Diagnosis and Molecular Biology

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03386916
Acronym
stasfa
Enrollment
80
Registered
2017-12-29
Start date
2010-01-31
Completion date
2018-09-30
Last updated
2017-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Image-Guided Biopsy - Carcinoma, Bronchogenic / Diagnosis- Outpatients

Keywords

Technology, Radiologic - Radiography, Interventional - Image-Guided Biopsy - Early Detection of Cancer - Carcinoma, Bronchogenic / diagnosis - Outpatients

Brief summary

In case of primary lung cancer, bone metastases biopsy can be done in initial diagnosis or follow-up. Nevertheless, any study focus on rentability and biopsy complications of lytic bone lesion for the context of lung cancer. This study aims to demonstrate that CT scan guide percutaneous biopsy of lytic bone lesion help to anatomopathologic diagnosis and molecular biology with a low complication rate inasmuch a lung cancer is suspected. This study is observational, retrospective, one center

Detailed description

Current progress in thoracic oncology require to be able to carry out analysis by molecular biology. So biopsies are done several times during cancer progression. But risk is high for a lung biopsy with enough sample, so a CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer can be an alternative. In case of primary lung cancer, bone metastases biopsy can be done in initial diagnosis or follow-up. But this contribution in diagnostic (anatomopathologic an molecular biology) is poorly understood. It is demonstrated that to sample on lytic bone lesion have a failure rate lower than on calcified osseous lesion. Nevertheless, any study focus on rentability and biopsy complications of lytic bone lesion for the context of lung cancer. this study aims to demonstrate that CT scan guide percutaneous biopsy of lytic bone lesion help to anatomopathologic diagnosis and molecular biology with a low complication rate inasmuch a lung cancer is suspected. This study is observational, retrospective, descriptive, one-center Patient's records selection will be done by keyword search on the CHU Grenoble Alpes radiology software. Only records with bone biopsy register between January 2010 and June 2017 will be included.

Interventions

PROCEDURECT scan guide percutaneous biopsy of lytic bone metastases of lung cancer

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* CT scan guide percutaneous biopsy of lytic bone metastases * register on CHU Grenoble Alpes radiology software between January 2010 and June 2017 * Patient who have a clinical context of lung cancer with bone metastases

Exclusion criteria

* Person deprived of liberty by judicial order * Opposition expressed by patient

Design outcomes

Primary

MeasureTime frameDescription
Rentability of biopsy of lytic bone lesion in anatomopathologic analysisAnalysis between january 2018-september 2018Rentability of biopsy of lytic bone lesion = 100x (number of sample wich analysed by anatomopathologic /total number of biopsy of lytic bone lesion done)

Secondary

MeasureTime frameDescription
Cell quality in sample of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosedAnalysis between january 2018-september 2018Cell quality in sample of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed * average percentage of tumour cells in samples
Rentability of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosedAnalysis between january 2018-september 2018Rentability of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed \- =100x (number of sample wich analysed by molecular biology /total number of biopsy of lytic bone lesion sent to molecular biology analysis)
Complication rate linked to gesture of biopsy of lytic bone lesionAnalysis between january 2018-september 2018Complication rate linked to gesture of biopsy of lytic bone lesion and descriptive analysis
Impact assessement of biopsy of lytic bone lesion on patient careAnalysis between january 2018-september 2018Modification of management of lung cancer between before biopsy and after biopsy results

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026